Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Fair Value Adjustment Of Warrants

Other segment segments

Gyre

-$89K+96.1%

All Other Segments

$0—

Similar metrics at other companies

RUMFair Value Adjustment Of Warrants

-$7M+68.0%

IBRXFair Value Adjustment Of Warrants

$295.41M+65,840%

SOC

SOCFair Value Adjustment Of Warrants

$44.16M+107%

BBNXFair Value Adjustment Of Warrants

$0-100%

VORFair Value Adjustment Of Warrants

$188.36M—

ASLEFair Value Adjustment Of Warrants

-$32K—

Other financials

Income statement

See full

Revenue$22.5M+2.1%

Gross profit$21.3M+0.6%

Operating income-$9.4M-512%

Net income-$8.7M-422%

EPS (diluted)-$0.10—

Balance sheet

See full

Cash & equivalents$37.5M+149%

Total debt$823.0K-48.1%

Total equity$101.3M+48.7%

Total assets$162.0M+24.8%

Cash flow

See full

Operating cash flow$3.2M+2,565%

CapEx$178.0K+45.9%

Free cash flow$3.0M+1,296%

Valuation

See full

Market cap$694.58M-4.7%

Enterprise value$657.9M-8.0%

P/S5.9×-1.3×

Profitability

See full

Gross margin95.1%-1.1pp

Operating margin-0.1%-10.4pp

Net margin6.3%+3.3pp

FCF margin2.6%—

Returns & leverage

See full

Return on equity8.2%+4.2pp

Debt / equity0×0.0×

Current ratio4.6×+1.0×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — fair value adjustment of warrants.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — fair value adjustment of warrants?: Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — fair value adjustment of warrants of $0 in Q1 2026.
What does gyre pharmaceuticals — fair value adjustment of warrants mean?: This represents the non-cash gains or losses resulting from changes in the market value of outstanding warrants issued by the company. It reflects the impact of financial market volatility on the company's balance sheet and reported earnings.